ARTICLES BY THIS AUTHOR
- 7/6/2011
Confused yet over when to start pelvic exams?
Changing Pap smear guidelines mean not all jurisdications are on the same page - 7/6/2011
Peanut components may improve allergy detection
Ara h2 may be most useful protein for more accurate diagnosis - 7/6/2011
LAST LAUGH: Medical Classified Ads
- 7/6/2011
Teens lose sleep due to heavy video gaming
Watching TV doesn’t have the same impact, U.S. study shows - 7/6/2011
Milder manifestations predict who may outgrow milk allergy
Ability to tell who will outgrow allergy has treatment implications - 7/6/2011
Psychotropic scripts increasing for Canadian kids
Second-generation antipsychotic use growing—all of it, off-label - 7/6/2011
Entecavir prevents hep B reactivation when starting chemo
Researchers suggest that patients with chronic hepatitis B virus (HBV) infection who must undergo cancer chemotherapy may avoid reactivation of HBV if they receive prophylaxis with entecavir (Baraclude). If HBV is reactivated because of chemotherapy-related immunosuppression, the patient’s treatment may be complicated by subsequent liver damage, hence the need to keep the virus in check.